**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77270

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Role of serum β2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy**

Yang B *et al*. β2-MG, HbA1c, and VEGF in DN

Bing Yang, Xiao-Hong Zhao, Guo-Bin Ma

**Bing Yang, Xiao-Hong Zhao, Guo-Bin Ma,** Department of Endocrinology and Metabolism, 3201 Hospital, Xi’an Jiaotong University Health Science Center, Hanzhong 723099, Shaanxi Province, China

**Author contributions:** Yang B contributed to conceptualization, data analysis, and writing; Zhao XH contributed to data analysis and writing; Ma GB revised the manuscript; and all authors have read and approved the manuscript.

**Corresponding author: Bing Yang, MM, Associate Chief Physician,** Department of Endocrinology and Metabolism, 3201 Hospital, Xi’an Jiaotong University Health Science Center, No. 783 Tianhan Avenue, Hanzhong 723099, Shaanxi Province, China. ybing3201@163.com

**Received:** May 6, 2022

**Revised:** June 18, 2022

**Accepted: July 6, 2022**

**Published online:**

**Abstract**

BACKGROUND

Diabetic nephropathy (DN) is a common complication of type 1 and type 2 diabetes that can lead to kidney damage and high blood pressure. Increasing evidence support the important roles of microproteins and cytokines, such as β2-microglobulin (β2-MG), glycosylated hemoglobin (HbA1c), and vascular endothelial growth factor (VEGF), in the pathogenesis of this disease. In this study, we identified novel therapeutic options for this disease.

AIM

To analyze the guiding significance of β2-MG, HbA1c, and VEGF levels in patients with DN.

METHODS

A total of 107 patients with type 2 diabetes mellitus complicated with nephropathy and treated in our hospital from May 2018 to February 2021 were included in the study. Additionally, 107 healthy individuals and 107 patients with simple diabetes mellitus were selected as the control groups. Changes in β2-MG, HbA1c, and VEGF levels in the three groups as well as the different proteinuria exhibited by the three groups were examined.

RESULTS

Changes in β2-MG, HbA1c, and VEGF levels in the disease, healthy, and simple diabetes groups were significantly different (*P* < 0.05). The expression of these factors from high to low were evaluated in different groups by pairwise comparison. In the disease group, high to low changes in β2-MG, HbA1c, and VEGF levels were noted in the massive proteinuria, microproteinuria, and normal urinary protein groups, respectively. Changes in these factors were positively correlated with disease progression.

CONCLUSION

The expression of serum β2-MG, HbA1c, and VEGF was closely correlated with DN progression, and disease progression could be evaluated by these factors.

**Key Words:** Type 2 diabetic nephropathy; β2-microglobulin; Glycosylated hemoglobin; Vascular endothelial growth factor; Disease progression

Yang B, Zhao XH, Ma GB. Role of serum β2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy. *World J Clin Cases* 2022; In press

**Core Tip:** This study investigated the relationship between diabetic nephropathy (DN) and the expression of serum β2-microglobulin (β2-MG), glycosylated hemoglobin (HbA1c), and vascular endothelial growth factor (VEGF). In total, 107 patients with type 2 diabetes mellitus complicated by nephropathy were included in this study. Additionally, 107 healthy individuals were included in the control group. The expression levels of these factors, from high to low, were evaluated in the different groups by pairwise comparison. Serum β2-MG, HbA1c, and VEGF were all closely correlated with DN progression based on all indicators.

**INTRODUCTION**

Diabetic nephropathy (DN) is a common clinical diabetic microangiopathy that is known to be an important cause of death in patients with end-stage renal disease[1]. Studies have reported that inflammatory reactions and vascular endothelial cell damage are important factors in the pathogenesis of DN[2]. β2-microglobulin (β2-MG) is a microprotein formed by lymphocytes, polymorphonuclear leukocytes, and platelets, which has a positive effect on the inflammatory response[3]. Glycosylated hemoglobin (HbA1c) levels can reflect the specific control of blood glucose levels in patients in recent months. Excessively elevated HbA1c levels indicate the worsening of hyperglycemic injury in patients, increasing the influence of hyperglycemia on the development of microvascular lesions[4]. Vascular endothelial growth factor (VEGF) reflects the development of capillary malformations caused by pathological changes to a certain extent, and the degree of kidney disease can be determined by analyzing the development of renal microvascular malformations[5]. Considering all of these, this study examined the relationship between the expression of serum β2-MG, HbA1c, and VEGF and the evaluation of DN patients, providing a scientific basis for clinical treatment and analysis of therapeutic effects.

**MATERIALS AND METHODS**

***Study population***

A total of 107 patients with type 2 diabetes complicated with nephropathy and treated in our hospital from May 2018 to February 2021 were included in the study. Among them, 59 were male and 48 were female, with a mean age of 49.27 ± 4.26 years old and mean body mass index (BMI) of 24.39 ± 1.54 kg/m2. These patients were divided into three groups based on urine protein content: normal urinary protein group, < 30 mg/g, 32 patients; microproteinuria group, 30–300 mg/g, 35 patients; and massive proteinuria group, > 300 mg/g, 40 patients. 107 healthy individuals and 107 patients with simple diabetes were recruited, and were established as the two control groups. There were no obvious differences in sex, age, or BMI among the five groups (*P* > 0.05) (Table 1). All recruited patients provided written informed consent, which was approved by the Ethics Committee.

The inclusion criteria were as follows: (1) diagnosis of DN[6]; (2) blood glomerular filtration rate < 15 mL/min; (3) serum creatinine level > 177 μmol/L; and (4) exhibited normal level of consciousness and ability to communicate.

The exclusion criteria were as follows: (1) tumors; (2) communication disorders; (3) any hormone therapy; (4) abnormal routine blood laboratory findings; and (5) refusal to cooperate with the treatment plan of this study.

***Enzyme-linked immunosorbent assay***

Four milliliters of fasting blood were extracted from all patients and centrifuged at 3500 r/min for 15 min. The supernatant of each sample was then collected, which were used to determine serum β2-MG, HbA1c, and VEGF levels by Enzyme-linked immunosorbent assay. All detection reagents were obtained from Roche Shanghai, and the operating procedures were strictly followed according to the manufacturer’s instructions.

***Observational index***

Changes in β2-MG, HbA1c, and VEGF levels in the disease, healthy, and simple diabetes groups were compared. In the disease group, the same three factors were compared between the normal, microproteinuria, and massive proteinuria groups. Moreover, the correlation between disease progression and β2-MG, HbA1c, and VEGF levels were also analyzed.

***Statistical analysis***

SPSS ver. 22.0 was used in the data analysis, and data were expressed as mean ± SE. Analysis of variance was used for multi-group comparisons and the least significant difference-*t* test was used for pairwise comparisons. The count data were expressed as (*n*) %, and the *χ*2 test was used. A *P*-value < 0.05 indicated a statistically significant difference.

**RESULTS**

***Comparison of changes in β2-MG, HbA1c, and VEGF levels in the disease, healthy, and simple diabetes groups***

The changes in β2-MG, HbA1c, and VEGF levels in the disease, healthy, and simple diabetes groups were significantly different (*P* < 0.05). Changes in β2-MG, HbA1c, and VEGF levels, from high to low, were noted in the disease, simple diabetes, and healthy groups, and the differences were statistically significant (*P* < 0.05, Table 2).

***Comparison of changes in β2-MG, HbA1c, and VEGF levels among the different disease groups***

There were statistically significant differences observed in terms of changes in β2-MG, HbA1c, and VEGF levels among the different disease groups (*P* < 0.05). β2-MG, HbA1c, and VEGF levels, from high to low, were noted in the massive proteinuria, microproteinuria, and normal urinary protein groups (Table 3).

***Correlation analysis***

Correlation analysis indicated that changes in serum β2-MG, HbA1c, and VEGF levels were positively correlated with disease progression in patients with DN, showing statistically significant differences for all three factors (*P* < 0.05, Table 4).

**DISCUSSION**

With an aging population in China, the lifestyle of patients with diabetes has changed significantly, resulting an increase in the incidence of diabetes annually[7]. Some studies have reported that diabetes is the third most common chronic non-communicable disease. In the disease progression of diabetes mellitus, the risk of DN gradually increases with continuous changes in the patient’s microvasculature[8]. Epidemiological investigations show that nearly 37.4% of patients with diabetes mellitus in China have different severities of DN[9]. Currently, the pathogenesis of DN is unclear, but most studies believe that carbohydrate and lipid metabolism disorders, hemodynamic changes, and abnormal secretion of cytokines lead to the often insidious onset of DN[10]. In most patients, DN manifests as massive proteinuria, which significantly affects patient safety. Considering these, thorough analysis of serological indicators, timely and effective assessment of the patient’s condition, and early preventive intervention should therefore have a positive effect on the prognosis of patients.

VEGF has a positive promoting effect on the proliferation of vascular endothelial cells, and is currently clinically considered an important indicator of diabetic retinopathy. It plays a critical role in the effective maintenance of the functional integrity of patients’ new blood vessels and endothelial cells[11]. In this study, VEGF levels increased significantly with the progression of the disease, suggesting that with the increase in VEGF levels, the risks of renal malformed vessels as well as vascular permeability changes significantly increase, ultimately resulting in the progression of DN. Through the comparison of VEGF levels in patients with diabetes mellitus, Wang *et al*[12] found that VEGF levels in patients with DN were distinctly higher than those in patients with simple diabetes, which was consistent with this study.

HbA1c has been a common indicator used to evaluate patients’ blood glucose control in recent months. The more obvious the increase in HbA1c level, the worse the blood glucose control[13,14]. However, excessive blood glucose levels can damage vascular endothelial cells in patients with DN and easily induce spasms of renal afferent arterioles, thus causing damage to the renal units due to ischemia and hypoxia[15,16]. In the early stages of the disease, kidney injury remains reversible to some extent. However, with gradual enhancement of kidney cell injury, the patient’s kidney self-repair ability is eventually lost. By this time, kidney transplantation or dialysis treatment is usually required, which seriously threatens a patient’s life[17,18]. Guo *et al*[19] analyzed the HbA1c level of patients with DN, and showed that the determination of HbA1c level in patients has a positive effect on early kidney injury. Yuan *et al*[20] obtained similar results.

β2-MG is a microglobulin protein that can be used as a clinical indicator of chronic kidney disease. During the progression of chronic kidney disease, the glomerular rate of patients significantly decreases as the severity of the disease increases, resulting in a large amount of microglobulin extravasation. In clinical treatment, the therapeutic effect and condition of patients can be determined according to serum β2-MG levels. In this study, β2-MG levels significantly increased as the degree of kidney injury increased, which is consistent with the results of Guo *et al*[19].

There are limitations to this study: (1) The sample size was limited to retrospective studies from a single center; these findings need further multi-institutional validation with a larger sample size[21]; and (2) This was a retrospective study that could not completely avoid missing data and measurement biases. Therefore, further studies must include more candidate biomarkers to develop predictive models in the future[22].

**CONCLUSION**

Our research shows that the expression of serum β2-MG, HbA1c, and VEGF are closely correlated with DN progression, and the progression of the disease can be evaluated by the expression of these factors in patients in the future.

**ARTICLE HIGHLIGHTS**

***Research background***

Diabetic nephropathy (DN) is a common complication of diabetes and is the leading cause of chronic kidney disease. Many identified biomarkers related to DN have been reported in previous studies, but none have been tested at bedside or in clinical trials. Moreover, their validation in larger patient cohorts and longitudinal studies are lacking.

***Research motivation***

Recent studies have demonstrated that inflammatory reactions and vascular endothelial cell damage are important factors in the pathogenesis of DN. The early detection of changes in renal function is of great benefit for the treatment of DN. Therefore, we aimed to analyze the significance of serum β2 microglobulin (β2-MG), glycosylated hemoglobin (HbA1c), and vascular endothelial growth factor (VEGF) levels in DN.

***Research objectives***

The objective of this study was to determine whether the expression levels of serum β2-MG, HbA1c, and VEGF are associated with DN.

***Research methods***

A total of 107 patients with type 2 diabetes mellitus complicated by nephropathy were included in the study, and 107 healthy individuals as well as 107 patients with simple diabetes mellitus were selected as the control groups. Changes in β2-MG, HbA1c, and VEGF levels in the three groups and the different proteinuria groups of the disease group were examined.

***Research results***

The expression levels of these factors were evaluated in different groups by pairwise comparison. Changes in β2-MG, HbA1c, and VEGF levels in the different disease groups were significantly different. By pairwise comparison, changes in β2-MG, HbA1c, and VEGF levels, from high to low, were noted in the massive proteinuria, microproteinuria, and normal urinary protein groups. Changes in these factors were positively correlated with disease progression.

***Research conclusions***

The expression of serum β2-MG, HbA1c, and VEGF are closely correlated with DN progression, and the progression of the disease can be evaluated by the expression of these factors in patients in the future.

***Research perspectives***

Diabetic kidney disease is a major health care challenge that complicates the course of many people living with diabetes. The current study showed that the 22 studied biomarkers had different levels of diagnostic accuracy, ranging from excellent to very good to good, and specificity values. The combined diagnosis of multiple biomarkers may improve the accuracy of early diagnosis of DN. In the future, optimization of biomarkers for clinical situations requires prospective validation in many patients with diabetic nephropathy, and needs to be performed in different critically ill populations.

**REFERENCES**

1 **Srivastava SP**, Zhou H, Setia O, Liu B, Kanasaki K, Koya D, Dardik A, Fernandez-Hernando C, Goodwin J. Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy. *Nat Commun* 2021; **12**: 2368 [PMID: 33888696 DOI: 10.1038/s41467-021-22617-y]

2 **Alomari G**, Al-Trad B, Hamdan S, Aljabali AAA, Al Zoubi MS, Al-Batanyeh K, Qar J, Eaton GJ, Alkaraki AK, Alshaer W, Haifawi S, Jemon K, Chellappan DK, Dua K, Tambuwala MM. Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin-induced type 1 diabetes in rats. *IET Nanobiotechnol* 2021; **15**: 473-483 [PMID: 34694755 DOI: 10.1049/nbt2.12026]

3 **Nongnuch A**, Kitiyakara C, Sappadungsuk S, Sathirapongsasuti N, Vipattawat K, Zhang P, Davies N, Davenport A. Pilot study to investigate differences in middle molecules, oxidative stress and markers of peripheral vascular disease in patients treated by high flux haemodialysis and haemodiafiltration. *PLoS One* 2021; **16**: e0258223 [PMID: 34614018 DOI: 10.1371/journal.pone.0258223]

4 **Ratra D**, Dalan D, Prakash N, Kaviarasan K, Thanikachalam S, Das UN, Angayarkanni N. Quantitative analysis of retinal microvascular changes in prediabetic and diabetic patients. *Indian J Ophthalmol* 2021; **69**: 3226-3234 [PMID: 34708778 DOI: 10.4103/ijo.IJO\_1254\_21]

5 **Zheng Q**, Wang Y, Yang H, Sun L, Fu X, Wei R, Liu YN, Liu WJ. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. *Front Pharmacol* 2020; **11**: 573645 [PMID: 33597868 DOI: 10.3389/fphar.2020.573645]

6 **Feng XF**, Li AM, Xu SL, Jia P, Shen SH. [Clinical value of glomerular filtration rate, urinary microalbumin, blood β 2-microglobulin and cystatin C in the diagnosis of diabetic nephropathy]. *Zhonghua Heyixue Yu Fenziyingxiangxue Zazhi* 2017; **37**: 331-336 [DOI: 10.3760/cma.j.issn.2095-2848.2017.06.003]

7 **Li Y**, Guo C, Cao Y. Secular incidence trends and effect of population aging on mortality due to type 1 and type 2 diabetes mellitus in China from 1990 to 2019: findings from the Global Burden of Disease Study 2019. *BMJ Open Diabetes Res Care* 2021; **9** [PMID: 34732399 DOI: 10.1136/bmjdrc-2021-002529]

8 **Huang Y**, Huang W, Zhang S, Jiang Y, Zhu JH. [Preliminary exploration on value of serum neutrophil gelatinase-associated lipocalin, high-sensitivity C-reaction protein, cystatian C and urine-microalbumin in early diagnosis of diabetic nephropathy]. *Shiyong Yufang Yixue* 2017; **24**: 1168-1171 [DOI: 10.3969/j.issn.1006-3110.2017.10.005]

9 **Bramham K**. Diabetic Nephropathy and Pregnancy. *Semin Nephrol* 2017; **37**: 362-369 [PMID: 28711075 DOI: 10.1016/j.semnephrol.2017.05.008]

10 **Hu M**, Wang R, Li X, Fan M, Lin J, Zhen J, Chen L, Lv Z. LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury *via* its interplay with β-catenin. *J Cell Mol Med* 2017; **21**: 2732-2747 [PMID: 28444861 DOI: 10.1111/jcmm.13189]

11 **Zhang XG**, Zhang YQ, Cheng QP, Cao Y, Sun JM, Lv XF. The impact of insulin pump therapy to oxidative stress in patients with diabetic nephropathy. *Eur J Med Res* 2018; **23**: 7 [PMID: 29433562 DOI: 10.1186/s40001-018-0304-2]

12 **Wang F**, Gao XY, Zhang R. [Changes and detection significance of serum inflammatory factors, vWf, VEGF and adhesion molecules in patients with diabetic nephropathy]. *Hainan Yixueyuan Xuebao* 2017; **23**: 2207-2210 [DOI: 10.13210/j.cnki.jhmu.20170816.004]

13 **Nally LM**, Wagner J, Sherr J, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M. A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. *Endocr Pract* 2021; **27**: 545-551 [PMID: 34120699 DOI: 10.1016/j.eprac.2020.11.017]

14 **Levin P**, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus. *Endocr Pract* 2021; **27**: 449-454 [PMID: 33853718 DOI: 10.1016/j.eprac.2020.10.004]

15 **Liu S**, Yang Y, Gao H, Zhou N, Wang P, Zhang Y, Zhang A, Jia Z, Huang S. Trehalose attenuates renal ischemia-reperfusion injury by enhancing autophagy and inhibiting oxidative stress and inflammation. *Am J Physiol Renal Physiol* 2020; **318**: F994-F1005 [PMID: 32068461 DOI: 10.1152/ajprenal.00568.2019]

16 **Nespoux J**, Patel R, Hudkins KL, Huang W, Freeman B, Kim YC, Koepsell H, Alpers CE, Vallon V. Gene deletion of the Na+-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. *Am J Physiol Renal Physiol* 2019; **316**: F1201-F1210 [PMID: 30995111 DOI: 10.1152/ajprenal.00111.2019]

17 **Campos CS**, Ferreira GF, Bastos KV, da Costa Carbogim F, de Brito Poveda V, de Araújo Püschel VA, Dos Santos KB. Immunosuppressive adherence after kidney transplantation in adult patients treated at an outpatient clinic: a better practice implementation project. *JBI Evid Implement* 2020; **19**: 306-314 [PMID: 34491926 DOI: 10.1097/XEB.0000000000000262]

18 **Yu H**, Liu D, Shu G, Jin F, Du Y. Recent advances in nanotherapeutics for the treatment and prevention of acute kidney injury. *Asian J Pharm Sci* 2021; **16**: 432-443 [PMID: 34703493 DOI: 10.1016/j.ajps.2020.11.001]

19 **Guo WH**, Zhang J. [The value of serum glycated albumin in early diagnosis of diabetic nephropathy]. *Jianyan Yixue Yu Linchuang* 2017; **14**: 27-29 [DOI: 10.3969/j.issn.1672-9455.2017.25.011]

20 **Yuan TF**, Li Y, Peng R. [Change of serum SCC andβ2-microglobulin in patients with chronic kidney disease and their correlation]. *Jianyan Yixue Yu Linchuang* 2017; **14**: 756-758 [DOI: 10.3969/j.issn.1672-9455.2017.06.005]

21 **Sen S**, Cohen AS. The Impact of Sample Size and Various Other Factors on Estimation of Dichotomous Mixture IRT Models. *Educ Psychol Meas* 2022 [DOI: 10.1177/00131644221094325]

22 **Sewell K**, Halanych JH, Russell LB, Andreae SJ, Cherrington AL, Martin MY, Pisu M, Safford MM. Blood Pressure Measurement Biases in Clinical Settings, Alabama, 2010-2011. *Prev Chronic Dis* 2016; **13**: E01 [PMID: 26741995 DOI: 10.5888/pcd13.150348]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the 3201 Hospital Institutional Review Board.

**Informed consent statement:** Informed consent was obtained from all study participants or their legal guardians prior to enrolment.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** Data supporting the findings of this study can be found within the article.

**STROBE statement:** The manuscript was prepared and revised according to the STROBE statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 6, 2022

**First decision:** June 7, 2022

**Article in press:**

**Specialty type:** Endocrinology and Metabolism

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Dascalu AM, Romania; Kilanowska A, Poland **S-Editor:** Wang JL **L-Editor:** A **P-Editor:** Wang JL

**Table 1 Comparison of baseline data among the five groups (mean ± SE)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | ***n*** | **Age (yr)** | **BMI (kg/m2)** | **Sex (male/female)** |
| Normal urinary protein group | 32 | 49.34 ± 4.28 | 24.33 ± 1.65 | 15/17 |
| Microproteinuria group | 35 | 49.22 ± 4.34 | 24.31 ± 1.51 | 15/20 |
| Massive proteinuria group | 40 | 49.25 ± 4.29 | 24.52 ± 1.52 | 29/11 |
| Healthy group | 107 | 49.72 ± 4.11 | 24.49 ± 1.62 | 55/52 |
| Simple diabetes group | 107 | 49.88 ± 4.69 | 24.59 ± 1.97 | 57/50 |
| *χ*2/*F* value | - | 0.281 | 0.259 | 8.142 |
| *P* value | - | 0.890 | 0.904 | 0.087 |

BMI: Body mass index.

**Table 2 Comparison of changes in β2-microglobulin, glycosylated hemoglobin, and Vascular endothelial growth factor levels in the disease, healthy, and simple diabetes groups (mean ± SE)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | ***n*** | **β2-MG (mg/L)** | **HbA1c (%)** | **VEGF (ng/L)** |
| Disease group | 107 | 4.34 ± 1.53 | 10.84 ± 1.81 | 176.69 ± 11.84 |
| Simple diabetes group | 107 | 2.56 ± 1.14 | 8.40 ± 1.24 | 137.84 ± 10.36 |
| Healthy groups | 107 | 1.11 ± 0.82 | 4.58 ± 0.95 | 109.32 ± 12.44 |
| *F* value |  | 195.518 | 558.284 | 912.281 |
| *P* value |  | 0.000 | 0.000 | 0.000 |
| LSD-*t* (disease *vs* simple diabetes) |  | 10.862 | 12.921 | 24.535 |
| *P* value |  | 0.000 | 0.000 | 0.000 |
| LSD-*t* (disease *vs* healthy) |  | 19.742 | 33.148 | 42.548 |
| *P* value |  | 0.000 | 0.000 | 0.000 |
| LSD-*t* (healthy *vs* simple diabetes) |  | 8.879 | 20.228 | 18.013 |
| *P* value |  | 0.000 | 0.000 | 0.000 |

LSD-*t*: Least significant difference; β2-MG: β2-microglobulin; HbA1c: Glycosylated hemoglobin; VEGF: Vascular endothelial growth factor.

**Table 3 Comparison of β2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels among the different disease groups (mean ± SE)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | ***n*** | **β2-MG (mg/L)** | **HbA1c (%)** | **VEGF (ng/L)** |
| Normal urinary protein group | 32 | 3.37 ± 1.32 | 9.26 ± 1.33 | 170.16 ± 10.62 |
| Microproteinuria group | 35 | 4.19 ± 1.39 | 10.57 ± 1.21 | 175.45 ± 10.39 |
| Massive proteinuria group | 40 | 5.26 ± 1.29 | 12.34 ± 1.35 | 182.99 ± 10.97 |
| *F* value |  | 18.250 | 51.067 | 13.179 |
| *P* value |  | 0.000 | 0.000 | 0.000 |
| LSD-*t* (normal urinary protein *vs* Microproteinuria) |  | 2.516 | 4.119 | 2.025 |
| *P* value |  | 0.013 | 0.000 | 0.045 |
| LSD-*t* (normal urinary protein *vs* massive proteinuria) |  | 5.981 | 9.994 | 5.066 |
| *P* value |  | 0.000 | 0.000 | 0.000 |
| LSD-*t* (microproteinuria *vs* massive proteinuria) |  | 3.471 | 5.887 | 3.051 |
| *P* value |  | 0.001 | 0.000 | 0.003 |

LSD-*t*: Least significant difference; β2-MG: β2-microglobulin; HbA1c: Glycosylated hemoglobin; VEGF: Vascular endothelial growth factor.

**Table 4 Correlation analysis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Index** | **β2-MG (mg/L)** | | **HbA1c (%)** | | **VEGF (ng/L)** | |
| ***r* value** | ***P* value** | ***r* value** | ***P* value** | ***r* value** | ***P* value** |
| Disease progression | 0.705 | 0.000 | 0.707 | 0.000 | 0.518 | 0.000 |

β2-MG: β2-microglobulin; HbA1c: Glycosylated hemoglobin; VEGF: Vascular endothelial growth factor.